MACC1 expression levels as a novel prognostic marker for colorectal cancer

Yamamoto,Hirofumi; Miyoshi,Norikatsu; Mimori,Koshi; Hitora,Toshiki; Tokuoka,Masayoshi; Fujino,Shiki; Ellis,Haley  L.; Ishii,Hideshi; Noura,Shingo; Ohue,Masayuki; Yano,Masahiko; Doki,Yuichiro; Mori,Masaki

doi:10.3892/ol.2014.2460

MACC1 expression levels as a novel prognostic marker for colorectal cancer

Authors:
- Hirofumi Yamamoto
- Norikatsu Miyoshi
- Koshi Mimori
- Toshiki Hitora
- Masayoshi Tokuoka
- Shiki Fujino
- Haley L. Ellis
- Hideshi Ishii
- Shingo Noura
- Masayuki Ohue
- Masahiko Yano
- Yuichiro Doki
- Masaki Mori
View Affiliations

Affiliations: Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Suita, Osaka 565‑0871, Japan, Department of Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Nakamichi, Osaka 537‑8511, Japan, Department of Molecular and Cellular Biology, Division of Molecular and Surgical Oncology, Kyushu University, Medical Institute of Bioregulation, Beppu, Osaka 874‑0838, Japan, Department of Surgery, Osaka Rosai Hospital, Sakai, Osaka 591‑8025, Japan, Department of Surgery, Yao Municipal Hospital, Yao, Osaka 581‑0069, Japan, Human Oncology and Pathogenesis Program, Memorial Sloan‑Kettering Cancer Center, New York, NY 10065, USA, Department of Frontier Science for Cancer and Chemotherapy, Osaka University, Yamadaoka, Suita, Osaka 565‑0871, Japan
Published online on: August 19, 2014 https://doi.org/10.3892/ol.2014.2460
Pages: 2305-2309

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Metastasis‑associated in colon cancer‑1 (MACC1) is key in promoting tumor proliferation and invasion, and is mediated by the hepatocyte growth factor (HGF) and mesenchymal‑epithelial transition factor. Previous reports have revealed that MACC1 is a novel oncogene that is expressed in various types of gastrointestinal cancer. The present study comprised of 174 patients who underwent curative surgery for colorectal cancer (CRC). The correlation between gene expression and clinical parameters of the patients was assessed. It was identified that patients exhibiting high MACC1 expression levels were statistically more susceptible to distant metastases and a poor prognosis, and those exhibiting low MACC1 expression showed improved disease‑free and overall survival than those with high expression. Therefore, the present data indicates that MACC1 expression levels may present as a prognostic factor in CRC patients.

View Figures

View References

1	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010.
2	Stein U and Schlag PM: Clinical, biological, and molecular aspects of metastasis in colorectal cancer. Recent Results Cancer Res. 176:61–80. 2007.
3	Birchmeier C, Birchmeier W, Gherardi E and Vande Woude GF: Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 4:915–925. 2003.
4	Mazzone M and Comoglio PM: The Met pathway: master switch and drug target in cancer progression. FASEB J. 20:1611–1621. 2006.
5	Sattler M and Salgia R: c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy. Curr Oncol Rep. 9:102–108. 2007.
6	Potempa S and Ridley AJ: Activation of both MAP kinase and phosphatidylinositide 3-kinase by Ras is required for hepatocyte growth factor/scatter factor-induced adherens junction disassembly. Mol Biol Cell. 9:2185–2200. 1998.
7	Watanabe T, Itabashi M, Shimada Y, et al: Japanese Society for Cancer of the Colon and Rectum: Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. Int J Clin Oncol. 17:1–29. 2012.
8	Sobin LH and Fleming ID: TNM classification of malignant tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer. 80:1803–1804. 1997.
9	Mimori K, Mori M, Shiraishi T, et al: Clinical significance of tissue inhibitor of metalloproteinase expression in gastric carcinoma. Br J Cancer. 76:531–536. 1997.
10	Mori M, Staniunas RJ, Barnard GF, et al: The significance of carbonic anhydrase expression in human colorectal cancer. Gastroenterology. 105:820–826. 1993.
11	Stein U: MACC1-a novel target for solid cancers. Expert Opin Ther Targets. 17:1039–1052. 2013.
12	Stein U, Walther W, Arlt F, et al: MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nat Med. 15:59–67. 2009.
13	André T, Quinaux E, Louvet C, et al: Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1. J Clin Oncol. 25:3732–3738. 2007.
14	Juneja M, Ilm K, Schlag PM and Stein U: Promoter identification and transcriptional regulation of the metastasis gene MACC1 in colorectal cancer. Mol Oncol. 7:929–943. 2013.
15	Zhang Y, Wang Z, Chen M, et al: MicroRNA-143 targets MACC1 to inhibit cell invasion and migration in colorectal cancer. Mol Cancer. 11:232012.
16	Wolpin BM and Mayer RJ: Systemic treatment of colorectal cancer. Gastroenterology. 134:1296–1310. 2008.
17	Kornmann M, Formentini A, Ette C, et al: Prognostic factors influencing the survival of patients with colon cancer receiving adjuvant 5-FU treatment. Eur J Surg Oncol. 34:1316–1321. 2008.
18	Bathe OF, Dowden S, Sutherland F, et al: Phase II study of neoadjuvant 5-FU + leucovorin + CPT-11 in patients with resectable liver metastases from colorectal adenocarcinoma. BMC Cancer. 4:322004.
19	Sadanandam A, Lyssiotis CA, Homicsko K, et al: A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med. 19:619–625. 2013.
20	Iijima M, Kano Y, Nohno T and Namba M: Cloning of cDNA with possible transcription factor activity at the G1-S phase transition in human fibroblast cell lines. Acta Med Okayama. 50:73–77. 1996.
21	Hansen WJ, Cowan NJ and Welch WJ: Prefoldin-nascent chain complexes in the folding of cytoskeletal proteins. J Cell Biol. 145:265–277. 1999.
22	Hodgson G, Hager JH, Volik S, et al: Genome scanning with array CGH delineates regional alterations in mouse islet carcinomas. Nat Genet. 29:459–464. 2001.
23	Lacy AM, García-Valdecasas JC, Delgado S, et al: Laparoscopy-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer: a randomised trial. Lancet. 359:2224–2229. 2002.
24	Weeks JC, Nelson H, Gelber S, et al: Short-term quality-of-life outcomes following laparoscopic-assisted colectomy vs open colectomy for colon cancer: a randomized trial. JAMA. 287:321–328. 2002.
25	No authors listed. Laparoscopically assisted colectomy is as safe and effective as open colectomy in people with colon cancer Abstracted from: Nelson H, Sargent D, Wieand HS, et al: for the Clinical Outcomes of Surgical Therapy Study Group. A comparison of laparoscopically assisted and open colectomy for colon cancer. N Engl J Med. 350:2050–2059. 2004.
26	Jayne DG, Guillou PJ, Thorpe H, et al; UK MRC CLASICC Trial Group. Randomized trial of laparoscopic-assisted resection of colorectal carcinoma: 3-year results of the UK MRC CLASICC Trial Group. J Clin Oncol. 25:3061–3068. 2007.
27	Koshariya M, Jagad RB, Kawamoto J, et al: An update and our experience with metastatic liver disease. Hepatogastroenterology. 54:2232–2239. 2007.